<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "DOXOrubicin inj VIAL>
<dose><value>50</value>
<value>40</value>
<value>60</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drug><value>DOXOrubicin inj VIAL</value>
</drug><strength><value>150 mg</value>
<value>50 mg</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>DAY 1 of 21. Administer dose by direct injection.</value>
</instruction><volume><value></value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. If Creatinine Clearance is greater than or equal to 50 mL/minute: Give as ordered. If Creatinine Clearance is less than 50 mL/minute: Contact physician. MAX Lifetime IV DOXOrubicin Dose: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2.</value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Contact physician. If Creatinine Clearance is greater than or equal to 50 mL/minute: Give as ordered. If Creatinine Clearance is less than 50 mL/minute: Contact physician. MAX Lifetime IV DOXOrubicin Dose: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2. </value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. MAX Lifetime IV DOXOrubicin Dose: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2. </value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. MAX Lifetime IV DOXOrubicin Dose: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2. [Part 1: Cycles 1, 2, 3, &amp; 4] </value>
</additionalnotes><population><value>cyclophosphamide, DOXOrubicin, vinCRIStine (CAV). Small Cell Lung Cancer.</value>
<value>DOXOrubicin/CISplatin/cyclophosphamide (PAC). Thymic Malignancy</value>
<value>CISplatin/DOXOrubicin/vinCRIStine/cyclophosphamide. Thymoma</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by DOCEtaxel. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by DOCEtaxel and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by PACLitaxel (weekly) and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3380</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3379</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>